1
|
Gay S, Lioger B, Kouchit Y, Decalonne L, Halimi J, Seitz-Polski B, Pillebout E, Ramdani Y, Maillot F, Alexandra A. Description d’une série de patients atteints de vascularite à IgA associée à des ANCA d’isotype IgA. Rev Med Interne 2022. [DOI: 10.1016/j.revmed.2022.10.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
2
|
Teisseyre M, Brglez V, Cremoni M, Benzaken S, Esnault V, Seitz-Polski B. Facteurs de risque de développement d’anticorps anti-rituximab dans la glomérulonéphrite extra-membraneuse. Nephrol Ther 2022. [DOI: 10.1016/j.nephro.2022.07.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
3
|
Wincup C, Dunn N, Ruetsch-Chelli C, Manouchehrinia A, Kharlamova N, Naja M, Seitz-Polski B, Isenberg D, Fogdell-Hahn A, Ciurtin C, Jury E. AB0433 ANTI-RITUXIMAB ANTIBODIES DEMONSTRATE NEUTRALISING CAPACITY, ASSOCIATE WITH LOWER CIRCULATING DRUG LEVELS AND EARLY RELAPSE IN PATIENTS UNDERGOING TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundA major limitation of biologic therapy is formation of anti-drug antibodies (ADA). We previously found ADA to rituximab (RTX) are more prevalent in patients undergoing treatment for systemic lupus erythematosus (SLE) than rheumatoid arthritis and vasculitis (1). In addition, we demonstrated that ADA to RTX predict subsequent infusion related reactions (2). However, little is known regarding the long-term dynamics of ADA to RTX in patients undergoing treatment for SLE.ObjectivesIn this study we evaluated the longitudinal impact of ADA positivity with particular focus on; 1) Risk factors for development of ADA. 2) Impact of ADA on treatment response. 3) Influence of ADA on RTX drug kinetics over time. 4) The capacity of ADA to neutralise RTX.MethodsPatients with SLE undergoing treatment with RTX were recruited to this study (n=35). Serum samples were collected at the following intervals post-treatment; 1-3 months (defined as ‘early’ post-treatment), 6 months, 12 months, 36 months (n=114).Clinical and laboratory data was collected pre-treatment and at each follow-up time point. Response to treatment was assessed by improvement in SLEDAI-2K score from baseline and also according to BILAG as previously described (3).ADA were detected using an electrochemiluminescent immunoassay. Serum RTX levels were measured by ELISA. ADA status was defined according to the following patterns over time; persistently negative, persistently positive (0-15 AU/ml) and persistently high positive (≥16 AU/ml, upper quartile). A complement dependent cytotoxic assay was used to determine neutralising capability of ADA in a subgroup of positive samples (n=38).ResultsADA to RTX were found to be persistently positive in 64.3% of patients over the 36-month follow-up period and there was no significant difference in baseline disease activity (BILAG / SLEDAI-2K) between those who were subsequently ADA positive vs negative. ADA positive patients had a younger age at diagnosis of SLE when compared with ADA negative (mean 22.50 ± 9.10 vs 37.29 ± 11.31 years, p=0.002, Figure 1 A). Multivariate logistic regression found a 22% decrease in risk of ADA positivity for each addition year after diagnosis (p=0.03).Figure 1.ADA positive patients had a significantly lower C3 level at baseline (mean 0.61 ± 0.23 g/L vs 0.87 ± 0.30 g/L, p=0.026), which remained lower at each subsequent time point post-treatment up to 12 months post-treatment (Figure 1B).At 1-3 months post-RTX, patients who were ADA positive had a significantly lower circulating drug level than ADA negative (p<0.001, Figure 1 C).In terms of clinical response, ADA positive patients had an initial significant improvement in disease activity (SLEDAI-2K) by 3 months (p<0.001). However, response was not maintained at 12 months (Figure 1 D). In comparison, ADA negative patients showed a significant improvement in SLEDAI-2K at 6 months and this was maintained across the 36-month follow-up period (Figure 1 E).BILAG defined relapse was more common at six months post-treatment in ADA positive patients (22%) and ADA highly positive patients (33%) than those who were ADA negative (in which there were no cases of relapse within the first six months, Figure 1 F). At 12-months post-RTX, a higher rate of BILAG defined Major Response was seen in those who were ADA negative (80%) when compared with ADA positive (44%) and high positive (36%) as shown in Figure 1 G.Finally, antibodies derived from all ADA positive samples (38/38) were found to neutralise RTX in vitro.ConclusionADA to RTX were common and persisted over the 36-month period of this study. ADA associated with earlier serum drug elimination, increased relapse rates and demonstrated neutralising capacity suggesting that ADA could be a significant limitation to sustained response to treatment in clinical practice.References[1]Faustini F et al. Arthritis research & therapy. 2021;23(1):211[2]Wincup C et al. Annals of the rheumatic diseases. 2019;78(8):1140-2[3]Md Yusof MY et al Annals of the rheumatic diseases. 2017;76(11):1829-36Disclosure of InterestsNone declared
Collapse
|
4
|
Vassallo M, Manni S, Pini P, Blanchouin E, Ticchioni M, Seitz-Polski B, Puchois A, Sindt A, Lotte L, Fauque P, Durant J. Patients with Covid-19 exhibit different immunological profiles according to their clinical presentation. Int J Infect Dis 2020; 101:174-179. [PMID: 33002623 PMCID: PMC7521203 DOI: 10.1016/j.ijid.2020.09.1438] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2020] [Revised: 09/22/2020] [Accepted: 09/22/2020] [Indexed: 02/07/2023] Open
Abstract
OBJECTIVES A novel beta coronavirus has been identified as responsible for the 2019 coronavirus infection (Covid-19). Clinical presentations range from asymptomatic cases to acute respiratory distress syndrome with fatal outcome. Such a broad spectrum of disease expression calls for an investigation of immune response characteristics. METHODS We identified subjects admitted for Covid-19 in whom a large panel of immunological markers were measured, including B- and T- and NK-lymphocyte phenotypes, T-lymphocyte subpopulation cells and plasma cytokines. Patients were divided according to symptom severity during hospitalisation, in those with uncomplicated and complicated infection. Differences between groups were analyzed. RESULTS Seventeen patients were included (mean age: 83 years; 9 women; mean delay of symptoms onset: 4 days). Six had uncomplicated infection, while 11 developed complicated forms during hospitalization. CD10 + B lymphocyte levels were inversely correlated with clinical severity (5.8% vs 2.0%, p = 0.04) and CD10+ levels above 3% were independently associated with uncomplicated forms [Odds Ratio 0.04 (CI 0.002-0.795, p = 0.034)]. TNF-alpha, IL-1, Il-6 and Il-8 measurements upon admission differed between patients who died and those who survived (p < 0.01 for all comparisons). CONCLUSIONS In a population of elderly patients recently infected with Covid-19, CD10 + B cell levels were inversely correlated with clinical severity. Cytokine values upon admission were highly predictive of fatal outcome during hospitalisation. These findings could explain differences in the clinical presentation and allow rapid identification of patients at risk for complications.
Collapse
Affiliation(s)
- M Vassallo
- Department of Internal Medicine/Infectious Diseases, Cannes General Hospital, Cannes, France.
| | - S Manni
- Department of Internal Medicine/Infectious Diseases, Cannes General Hospital, Cannes, France
| | - P Pini
- Department of Internal Medicine/Infectious Diseases, Cannes General Hospital, Cannes, France
| | - E Blanchouin
- Department of Internal Medicine/Infectious Diseases, Cannes General Hospital, Cannes, France
| | - M Ticchioni
- Laboratory of Immunology, Nice University Hospital, Université Côte d'Azur, Nice, France
| | - B Seitz-Polski
- Laboratory of Immunology, Nice University Hospital, Université Côte d'Azur, Nice, France
| | - A Puchois
- Multipurpose Laboratory, Bacteriology and Virology Unit, Cannes General Hospital, Cannes, France
| | - A Sindt
- Multipurpose Laboratory, Bacteriology and Virology Unit, Cannes General Hospital, Cannes, France
| | - L Lotte
- Multipurpose Laboratory, Bacteriology and Virology Unit, Cannes General Hospital, Cannes, France
| | - P Fauque
- Institut Polyclinique de Cannes (IPOCA), Cannes, France
| | - J Durant
- Infectious Diseases Department, Nive University Hospital, Université Côte d'Azur, Nice, France
| |
Collapse
|
5
|
Boyer-Suavet S, Cremoni M, Dupeyrat T, Zorzi K, Brglez V, Benzaken S, Esnault V, Seitz-Polski B. Functional immune assay using interferon-gamma could predict infectious events in end-stage kidney disease. Clin Chim Acta 2020; 502:287-292. [DOI: 10.1016/j.cca.2019.11.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2019] [Revised: 11/13/2019] [Accepted: 11/13/2019] [Indexed: 12/19/2022]
|
6
|
Lateb M, Payre C, Brglez V, Boyer-Suavet S, Zaidan M, Jourde-Chiche N, Courivaud C, Esnault V, Lambeau G, Seitz-Polski B. Pathogénicité des anticorps anti-PLA2R1 médiée par l’activation du complément dans la glomérulonéphrite extra-membraneuse in vitro. Nephrol Ther 2019. [DOI: 10.1016/j.nephro.2019.07.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Cremoni M, Brglez V, Andreani M, Boyer-Suavet S, Gérard A, Benzaken S, Esnault V, Seitz-Polski B. Rôle de l’environnement dans le profil cytokinique des glomérulonéphrites extra-membraneuses. Nephrol Ther 2019. [DOI: 10.1016/j.nephro.2019.07.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Cremoni M, Boyer-Suavet S, Dupeyrat T, Benzaken S, Esnault V, Seitz-Polski B. Étude de l’immunité cellulaire non spécifique des patients atteints d’un syndrome néphrotique par un test à l’interféron gamma. Nephrol Ther 2018. [DOI: 10.1016/j.nephro.2018.07.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
9
|
Boyer S, Benzaken S, Bernard G, Esnault V, Seitz-Polski B. Réactivité croisée des anticorps anti-rituximab neutralisants avec les anti-CD20 de troisième génération : une alternative thérapeutique dans la glomérulopathie extramembraneuse ? Nephrol Ther 2017. [DOI: 10.1016/j.nephro.2017.08.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Montaudié H, Seitz-Polski B, Cornille A, Benzaken S, Passeron T. Interleukin-6 et protéine C réactive ultra-sensible : marqueurs prédictifs potentiels de réponse aux anti-TNF-alpha dans l’hidrosadénite suppurée. Ann Dermatol Venereol 2016. [DOI: 10.1016/j.annder.2016.09.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
11
|
Seitz-Polski B, Debiec H, Dahan K, Lochouarn M, Benzaken S, Bernard G, Ronco P, Esnault V. Immunomonitorage du rituximab au cours du traitement des glomérulonéphrites extramembraneuses. Nephrol Ther 2016. [DOI: 10.1016/j.nephro.2016.07.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Roriz M, Seitz-Polski B, Aldigier J, Thervet É, Augusto J, Braconnier A, Esnault V, Halimi J, Gatault P. Glomérulonéphrite extracapillaire avec dépôts mésangiaux d’IgA E et présence d’ANCA IgG : une nouvelle entité ? Rev Med Interne 2016. [DOI: 10.1016/j.revmed.2016.04.163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
13
|
Lochouarn M, Lambeau G, Esnault V, Benzaken S, Sadoul J, Panaia Ferrari P, Hofman P, Bernard G, Seitz-Polski B. Prévalence de l’association entre glomérulonéphrite extramembraneuse et autoanticorps antithyroïdiens. Nephrol Ther 2015. [DOI: 10.1016/j.nephro.2015.07.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
Seitz-Polski B, Dolla G, Payré C, Benzaken S, Bernard G, Esnault V, Lambeau G. Un phénomène de spreading intramoléculaire des épitopes de PLA2R1 est associé à des formes sévères de glomérulonéphrite extramembraneuse. Nephrol Ther 2015. [DOI: 10.1016/j.nephro.2015.07.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
15
|
Seitz-Polski B, Payre C, Cassuto E, Bernard G, Albano L, Burtey S, Bataille S, Mariat C, Krummel T, Moulin B, Lambeau G, Esnault V. ELISA spécifique pour le suivi des anticorps anti-PLA2R1 avant et après transplantation rénale. Nephrol Ther 2012. [DOI: 10.1016/j.nephro.2012.07.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
16
|
Seitz-Polski B, Boullenger F, Cassuto E, Frémeaux-Bacchi V, Favre G, Islam S, Esnault V. Aspects cliniques des mutations du gène codant pour le facteur I : à propos de trois cas cliniques. Nephrol Ther 2011. [DOI: 10.1016/j.nephro.2011.07.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
17
|
Berguignat M, Payre C, Lambeau G, Cassuto E, Esnault V, Seitz-Polski B. Les auto-anticorps dirigés contre le récepteur des phospholipases A2 (PLA2R) sont-ils prédictifs d’une récidive de glomérulonéphrite extramembraneuse (GEM) en transplantation rénale ? Nephrol Ther 2011. [DOI: 10.1016/j.nephro.2011.07.046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
18
|
Mosconi E, Rekima A, Seitz-Polski B, Kanda A, Fleury S, Tissandie E, Monteiro R, Dombrowicz DD, Julia V, Glaichenhaus N, Verhasselt V. Breast milk immune complexes are potent inducers of oral tolerance in neonates and prevent asthma development. Mucosal Immunol 2010; 3:461-74. [PMID: 20485331 DOI: 10.1038/mi.2010.23] [Citation(s) in RCA: 168] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Allergic asthma is a chronic lung disease resulting from an inappropriate T helper (Th)-2 response to environmental antigens. Early tolerance induction is an attractive approach for primary prevention of asthma. Here, we found that breastfeeding by antigen-sensitized mothers exposed to antigen aerosols during lactation induced a robust and long-lasting antigen-specific protection from asthma. Protection was more profound and persistent than the one induced by antigen-exposed non-sensitized mothers. Milk from antigen-exposed sensitized mothers contained antigen-immunoglobulin (Ig) G immune complexes that were transferred to the newborn through the neonatal Fc receptor resulting in the induction of antigen-specific FoxP3(+) CD25(+) regulatory T cells. The induction of oral tolerance by milk immune complexes did not require the presence of transforming growth factor-beta in milk in contrast to tolerance induced by milk-borne free antigen. Furthermore, neither the presence of IgA in milk nor the expression of the inhibitory FcgammaRIIb in the newborn was required for tolerance induction. This study provides new insights on the mechanisms of tolerance induction in neonates and highlights that IgG immune complexes found in breast milk are potent inducers of oral tolerance. These observations may pave the way for the identification of key factors for primary prevention of immune-mediated diseases such as asthma.
Collapse
|